Serological survey of antibodies against SARS-CoV-2 in dogs and cats, Thailand개와 고양이에서 SARS-CoV-2에 대한 항체의 혈청학적 조사, 태국Article Published on 2022-07-012022-09-12 Journal: Transboundary and emerging diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory disease acute respiratory syndrome affecting antibody cats caused clinically collected conducted COVID-19 COVID-19 outbreak disease dogs ELISA enzyme-linked immunosorbent Evidence Health healthy mild respiratory Neutralizing antibodies neutralizing antibody positive SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody second wave serological survey serum sample survey sVNT tested Thailand virus virus neutralization test [DOI] 10.1111/tbed.14208 PMC 바로가기 [Article Type] Article
Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals해양 연체 동물 추출물-SARS-CoV-2 항바이러스제의 잠재적 공급원Review Published on 2022-07-012022-09-11 Journal: Reviews in Medical Virology [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adenovirus Antiviral antiviral action antiviral activity causative agent clinically coronavirus coronavirus disease Coronavirus disease 2019 demonstrated effective Evidence Hemolymph herpes simplex herpes simplex virus human coronavirus human coronaviruses in silico in vitro innate immune system Mollusca molluscs. Pacific oyster Pacific oyster (Crassostrea gigas) phylum PROTECT SARS-CoV-2 SARS-CoV-2 antivirals severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 silico studies treat virus virus particle viruses [DOI] 10.1002/rmv.2310 PMC 바로가기 [Article Type] Review
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessmentdaclatasvir와 Sofosbuvir 및 COVID-19 환자의 결과: GRADE 평가를 통한 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-07-012022-09-11 Journal: Postgraduate medical journal [Category] 임상, [키워드] Admission certainty of evidence chance clinical clinical pharmacology clinical recovery clinically control group Controlled trial COVID-19 daclatasvir database databases death defined estimate evaluate the effect ICU ICU admission IMV inception increase in Infectious diseases intensive care intensive care unit internal medicine intervention group Invasive mechanical ventilation lower mortality Meta-analysis moderate Mortality mortality rate outcome Patient patients with COVID-19 performed Primary outcome randomised controlled trial reduce mortality rate reduced reported risk ratio risk ratios risk reduction RRs secondary outcome Secondary outcomes sofosbuvir sofosbuvir/daclatasvir Standard of care systematic literature search systematic review Virology [DOI] 10.1136/postgradmedj-2021-140287 PMC 바로가기 [Article Type] Meta-Analysis
Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infectionSARS Cov2 원형, Delta 및 Omicron 변이체 감염을 억제하는 잠재적인 COVID-19 치료 화합물의 식별Article Published on 2022-07-012022-09-11 Journal: Virology [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료법, 치료제, [키워드] Anti-viral drug repurposing apilimod approach berbamine candidate drug cell death Cepharanthine clinical trial clinically Compound compounds COVID-19 COVID19 crizotinib Delta drug drug candidate effort FDA approval followed by Health identification Infection inhibit inhibited inhibitory effect less library multiple cell lines omicron Omicron variant Omicron variants Probability pseudovirus entry Recurrent replicated repurposing required robustness safety profile SARS CoV2 screened stratified Treatment Validity variant [DOI] 10.1016/j.virol.2022.05.004 PMC 바로가기 [Article Type] Article
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID studyObservational Study Published on 2022-07-012022-10-04 Journal: Intensive care medicine [Category] 임상, [키워드] Administered administration affected age Analysis assessment Bacterial baseline benefit Care clinically Corticosteroid corticosteroid treatment Corticosteroids covariate COVID-19 COVID-19 patient Critically ill Critically ill patient Dexamethasone dosage dose doses of corticosteroid early administration Evidence failure higher risk hospitalisation ICU ICU admission ICUs Illness severity in-hospital mortality increased risk Inflammation information intensive care interaction term Invasive mechanical ventilation investigated Laboratory lower risk Major mechanical ventilation Modification Mortality multivariable analysis no effect nosocomial Observational cohort study organ damage Patient patients with COVID-19 performed personalised Pneumonia potential benefit Primary outcome Protective receiving severe coronavirus disease severity Significant SOFA Spanish steroid subgroup subgroups subgroups of patient symptom onset systemic corticosteroid Treatment use of corticosteroid variable with COVID-19 [DOI] 10.1007/s00134-022-06726-w PMC 바로가기 [Article Type] Observational Study
Eye Infection with SARS-CoV-2 as a Route to Systemic Immunization?전신 면역을 위한 경로로서 SARS-CoV-2에 의한 눈 감염?Article Published on 2022-06-302022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 치료기술, [키워드] airway airways animals antibody Blood Case report case reports clinically Conjunctiva conjunctivitis Control control group Cornea Cytotoxic antibody detectable determine disease disease symptoms experiments eye eyes followed by General disease group hamster Immunity immunization induce Infection infection with SARS-CoV-2 Infectious diseases lethargic Local lost weight MALT material mucosa negative control observation ocular Primary infection reduced respiratory tract route SARS-CoV-2 SARS-CoV-2 conjunctivitis SARS-CoV2 subsequent systemic treated virus was recorded weight weight gain Wuhan [DOI] 10.3390/v14071447 PMC 바로가기 [Article Type] Article
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens Research Published on 2022-06-302022-10-05 Journal: NPJ Digital Medicine [Category] 신약개발, 임상, 치료법, 치료제, [키워드] adjusted B.1.351 B.1.617.2 Beta candidate drug clinically clinician combination regimen combination therapy combinations Community COVID-19 Delta drug combination Drug interactions Efficacy EIDD-1931 experimental validation Infectious disease Live virus pandemic platform Rapid regimen representing SARS-CoV-2 SARS-CoV-2 variant therapy translation Vero E6 was used [DOI] 10.1038/s41746-022-00627-4 [Article Type] Research
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts면역이 저하된 숙주에서 장기간 감염되는 동안 SARS-CoV-2 스파이크 돌연변이의 출현Article Published on 2022-06-292022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료제, [키워드] accumulating acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 case sery clinically Containment Containment measure containment measures coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated described Early detection emergence escape mutation Evidence genomic globe highlight Host Immunocompromised immunocompromised hosts Immunocompromised patient Immunocompromised patients implicated Infection infection control Measures mutated Mutation pandemic PCR positivity persistent infections Prolonged Prolonged COVID-19 public health respiratory reverse transcription SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 variants Sequence analysis spike spike mutation spike mutations Spike protein sustained the spike protein therapeutic Therapeutics Treatment unique Vaccine variant variants [DOI] 10.1128/spectrum.00791-22 PMC 바로가기 [Article Type] Article
Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)Randomized Controlled Trial Published on 2022-06-292022-10-05 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료법, 치료제, [키워드] 95% CI adverse event age anti-inflammatory property Anti-viral ARMS assigned chose clinically coronavirus disease COVID-19 demonstrated determine double-blind Effect FDA female group Hospitalization incidence IND measure Mild mitigate one patient outcome Outpatient participant Patient Phase 2 study Placebo placebo-controlled Pneumonia primary outcome measure randomization Randomly receive recruited resveratrol single dose small sample size statistically Symptom treated Treatment Trial Vitamin D3 was determined was used [DOI] 10.1038/s41598-022-13920-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
The genetic architecture of pneumonia susceptibility implicates mucin biology and a relationship with psychiatric illness Research Published on 2022-06-292022-10-05 Journal: Nature Communications [Category] 신약개발, 유전자 메커니즘, [키워드] Analysis association cause clinically correlation death Diagnosis Evidence Genetic genetic architecture genetics histocompatibility complex region identify implicated mapped Meta-analysis MUC5AC Necrosis overlap pathway phenotype Pneumonia Precision Psychiatric receptor risk risk score smoking Support susceptibility target targets TNFRSF1A Treatment utilised variant widespread [DOI] 10.1038/s41467-022-31473-3 [Article Type] Research